.png)
SummaryGermany is the gateway market for European pharmaceutical access because it is the only large European system that lets a manufacturer sell at a self set price from the day of authorisation, with statutory reimbursement from day one and no prior price approval, and because the resulting German price is then picked up by the reference pricing systems of a large part of Europe. Launching in Germany therefore buys two things at once: early revenue, and an anchor price that travels.
That is the standard argument, and it is still broadly correct. It is also incomplete, and repeating it uncritically has cost companies money. Since the GKV financial stabilisation reforms, the free pricing window is shorter than most English language guidance assumes, the negotiated price bites earlier, and a set of statutory guardrails now constrains where the negotiation can land. This article makes the case for Germany first, and then makes the case against it, so that the decision is a real one.
Germany is the largest pharmaceutical market in Europe and among the largest in the world, but almost every figure in circulation is quoted without saying what it counts. That is the single most common error in market entry business cases, because the same country can appear to be worth 49 billion euros or 64 billion euros depending on which boundary is drawn, and the two numbers are not interchangeable.
| Scope | Approximate value (2024) | What it includes | What it excludes |
|---|---|---|---|
| German pharmacy market | around 49 billion euros | Medicines dispensed through public pharmacies, prescription and non prescription, measured at pharmacy retail level | Hospital supply, direct to clinic sales, veterinary medicines, exports |
| Total German pharmaceutical market | around 64 billion euros | The pharmacy market plus hospital and clinic channels and other non pharmacy distribution | Exports, active ingredient trade |
| Statutory health insurance medicines expenditure | A subset of both, net of statutory rebates and negotiated reimbursement amounts | What the sickness funds actually pay after rebates | Private insurance, self pay, list price margins already rebated away |
Three practical rules follow. First, never model revenue on a market figure whose channel scope you cannot name. Second, list price based market sizes overstate realisable revenue in Germany more than in most countries, because statutory rebates and negotiated reimbursement amounts are deducted after the fact. Third, if your product is hospital only, the pharmacy market number is not your market at all.
Germany separates market authorisation from price regulation, and almost no other large European system does. Once a medicine holds a valid marketing authorisation, it may be placed on the German market immediately, it is reimbursable by the statutory health insurance system from that day, and the manufacturer sets the launch price itself. There is no price approval step, no reimbursement listing application and no positive list gate to clear before the first pack ships.
Compare that with the pattern elsewhere in Europe. In France, Spain, Italy and most other large systems, a medicine cannot be reimbursed until a pricing and reimbursement decision has been taken, and those procedures routinely run many months after EU authorisation. The commercial consequence is blunt: in Germany the revenue clock starts at approval, and in most of Europe it starts at the end of a negotiation.
This is the actual content of the phrase "gateway market". It is not that Germany is culturally central or geographically convenient. It is that Germany is the one large European market where the regulatory decision alone is sufficient to start selling.
External reference pricing, sometimes called international reference pricing, is the practice of setting or negotiating a national price by looking at the prices of the same product in a defined basket of other countries. Germany sits in a very large number of those baskets. A peer reviewed overview of European external reference pricing systems by Rémuzat and colleagues found Germany among the three most frequently referenced countries in Europe, referenced by 17 national systems, alongside France and the United Kingdom. The full comparison is published in the Journal of Market Access and Health Policy.
Germany is attractive as a reference source for a structural reason worth understanding: German prices are formed domestically, through benefit assessment and negotiation, rather than by referencing other countries. A country that references Germany therefore imports a price that was independently derived, not a circular average of its neighbours.
For a manufacturer, this cuts both ways and the second edge is sharper than the first. A strong German price supports prices across a large part of Europe. A weak German price, or an early German price cut, propagates just as efficiently, and it does so on a schedule set by other countries' revision cycles rather than yours. Sequencing decisions that treat Germany as an isolated national P and L are, in effect, setting European prices by accident.
"It's a pain to search them all individually. Especially when you want to look in 20 different countries, it's a pain." Manager, healthcare service provider
Germany is consistently among the fastest European markets from EU authorisation to actual availability, and the reason is entirely structural rather than administrative goodwill. A centralised marketing authorisation granted by the European Commission after a positive CHMP opinion is valid in all EU and EEA member states at once, and the European Medicines Agency publishes the step by step procedure. What differs between member states is everything that happens after that authorisation.
In Germany, the remaining steps to commercial availability are operational, not gating:
National authorisation routes remain available for products where the centralised procedure is optional or inapplicable, and BfArM describes the national, decentralised and mutual recognition procedures. For most innovative products, though, the relevant point is that the German launch is limited by your own operational readiness rather than by a payer decision.
The German bargain is explicit: fast market entry at a price you choose, followed by a negotiated price you do not choose. Every medicine with a new active substance enters the AMNOG early benefit assessment, in which the Federal Joint Committee (G-BA) determines the extent of added benefit against a comparator therapy it defines, and the manufacturer then negotiates a reimbursement amount with the National Association of Statutory Health Insurance Funds. The procedure and all resolutions are published in English by the G-BA.
| Phase | Timing from launch | What happens | Commercial consequence |
|---|---|---|---|
| Free pricing | Months 0 to 6 | Manufacturer sets the price; product is reimbursed at that price | Revenue at list price, but this is also the price other countries observe |
| Benefit assessment | Months 0 to 6 | Dossier at launch, assessment (usually via IQWiG), written comment, oral hearing, G-BA resolution within six months | The comparator definition, not the trial data alone, drives the outcome |
| Price negotiation | From the G-BA resolution | Negotiation of the reimbursement amount, arbitration board if no agreement | Statutory guardrails constrain the achievable range |
| Negotiated price applies | From month 7, retroactively | The agreed reimbursement amount is applied back to the start of month 7 | A rebate liability accrues while you are still negotiating |
The month seven rule is the change that most often catches teams out. Under the rules in force since the GKV financial stabilisation act, the free pricing period is six months and the negotiated reimbursement amount takes effect retroactively from the beginning of the seventh month after launch. Earlier guidance describing a twelve month free pricing period is describing a rule that no longer applies. Cash flow models built on twelve months of list price revenue will book revenue that is subsequently clawed back.
The German payer landscape is unusually simple to address for a market of this size. Roughly 90 percent of the population is covered by statutory health insurance according to the GKV-Spitzenverband, which corresponds to around 74 million insured people, with most of the remainder in substitutive private health insurance. Coverage is close to universal and the benefits catalogue is defined collectively rather than plan by plan.
Three structural features matter for a market entry plan:
Anyone still describing Germany as an unambiguously premium launch market is working from a pre 2023 picture. Several changes have compressed the German value case, and a balanced entry decision has to price them in.
Put together: Germany still offers the fastest revenue start in large European markets, but it no longer offers a long protected window at your own price, and the reference benefit is no longer automatic.
Germany first is a default, not a law. It is the wrong choice in several identifiable situations, and recognising them early saves a great deal of rework:
Every argument above resolves into the same operational requirement: you need current, comparable product and price data for Germany and for the countries that reference it, in one place, at the same moment in time. Which comparator products exist and in which pack sizes, which sit in a reference price group, which are currently in short supply and therefore substituted, and which active substance is available in which country at what price. That information sits in separate national registries, in different languages, updated on different cycles, which is why so much European launch planning is still done with spreadsheets and manual country by country lookups.
pharmazie.com consolidates 25+ pharmaceutical databases into a single search, covering more than 50,000 German products and more than 120,000 international products across 50+ countries, including daily updated German supply shortage data with international alternatives. For launch sequencing and reference price modelling, that is the most complete single answer to cross layer and cross border questions across DACH and 50+ countries, and it replaces the country by country research that makes European launch planning slow. DACON has maintained this data since 1989.
This content is intended for healthcare professionals and does not constitute medical advice. Last reviewed: July 2026.
